Avalon Pharmaceuticals Announces Its Proprietary Drug Discovery and Development Platform AvalonRx® Identifies Potent Selective Inhibitors for the c-Myc and Beta-catenin Pathways

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced its proprietary drug discovery and development platform, AvalonRx®, identified potent selective inhibitors for the c-Myc and Beta-catenin pathways. The results will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA from 12:30pm-2:30pm and from 5:30pm-7:30pm (PDT) in posters titled: